Technology 24 of 266
Bioinformatics
12 EIC Accelerator winners build on Bioinformatics, 1% of the classified companies, in 2 sectors and 4 industries.
12
Companies
2
Sectors
4
Industries
8
Countries
0%
Exits
17%
Show signs of scaling
Sectors
- Health11 (92%)
- Agrifood1 (8%)
Used together with
Other technologies of the same companies
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Bioinformatics
Show the numbers
| Companies | Bioinformatics | |
|---|---|---|
| 2019 | 1 | 1 |
| 2020 | 1 | 1 |
| 2021 | 4 | 4 |
| 2022 | 3 | 3 |
| 2023 | 3 | 3 |
| 2024 | 0 | 0 |
What happened to them (12 of 12 checked)
- Active9 (75%)
- Exit0 (0%)
- Failed3 (25%)
- Other0 (0%)
Signs of scaling
- Scaling2 (17%)
- Not scaling5 (42%)
- Scaling unclear5 (42%)
Keywords
- Antimicrobial resistance
- Antivirals
- Bacterial infections
- Benchtop kits
- Biased signalling
- Biomarker discovery
- Bladder cancer
- Climate resilience
- Clinical genomics
- Colorectal cancer
- COVID-19
- Drought tolerance
- Drug design
- Drug repurposing
- Drug target discovery
- Dysbiosis
- Endogenous retroviruses
- Gene fusions
- Genetic testing
- GPCR
- Gut microbiome
- Influenza
- Leukaemia
- Malting barley
- Neoantigens
- Obesity
- Oncology
- Optical DNA mapping
- Ovarian cancer
- Pathogen detection
- Personalised immunotherapy
- Personalised medicine
- Phage therapy
- Plant breeding
- Precision nutrition
- Public data repositories
- Rare diseases
- Research laboratories
- RNA sequencing
- Sequencing data analysis
All 12 companies using Bioinformatics
| Company | Project | Industry | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|---|
| QLUCORE AB | QIandQDThe first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer | In vitro diagnostics | Sweden | November 2023 | Grant only | Active | Deep dive |
| ErVaccine Technologies | OVACellDevelopment of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer | Biopharmaceuticals | France | June 2023 | Blended finance | Active | Deep dive |
| NEOGAP Therapeutics AB | NEOpTTLInnovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement | Biopharmaceuticals | Sweden | March 2023 | Blended finance | Active | Deep dive |
| Camino Science sp. z o.o. | in silico bio-evolutioin silico bio-evolutio - novel AI paradigm for molecular biology | Biopharmaceuticals | Poland | March 2022 | Grant first | Active | Deep dive |
| Computomics GmbH | TRAIT4.0TRansition to agriculture 4.0: increasing crop resiliency with Artificial Intelligence Technology | Digital agriculture | Germany | March 2022 | Blended finance | Active | Deep dive |
| Scipio bioscience | DEEP-IN-CELLInnovative single-cell RNA-seq kit to detect the rarer and more significant cellular genomic expressions | Life science tools | France | March 2022 | Blended finance | Insolvent | Deep dive |
| Epigene Labs SAS | mCUBEMulti-omic data driven drug discovery and indication prioritisation platform in oncology | Life science tools | France | October 2021 | Blended finance | Insolvent | Deep dive |
| SEQUENTIA BIOTECH SL | MICKTranslational Microbiome Platform | In vitro diagnostics | Spain | October 2021 | Blended finance | Active | Deep dive |
| enGenome srl | eVaiA novel bioinformatics SaaS platform to identify and classify the pathogenicity of single genomic variants and oligogenic variant combinations for the diagnosis and treatment of genetic diseases | In vitro diagnostics | Italy | June 2021 | Grant first | Active | Deep dive |
| Perseus Biomics BV | Perseus MAPMicrobiome Abundance Profiling: Precision microbiome profiling for insights into human health & research | Life science tools | Belgium | June 2021 | Blended finance | Active | Deep dive |
| SIGNIA THERAPEUTICS SAS | SigniaAn innovative drug development and repurposing platform for rapid identification and validation of antimicrobial therapeutics | Biopharmaceuticals | France | January 2020 | Grant only | Closed | Deep dive |
| InterAx Biotech AG | PICARDDISRUPTIVE GPCR LEAD DISCOVERY PLATFORM DELIVERING NEW AND SAFER THERAPEUTICS | Biopharmaceuticals | Switzerland | June 2019 | Grant only | Active | Deep dive |